Slideshows Images Quizzes

Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. See additional information.

Persantine IV

Last reviewed on RxList: 7/24/2017
Persantine IV Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Last reviewed on RxList 7/24/2017

Persantine IV (dipyridamole) is a coronary vasodilator used as an alternative to exercise in thallium myocardial perfusion imaging for the evaluation of coronary artery disease in patients who cannot exercise adequately. The brand name Persantine IV is discontinued but generic versions may be available. Common side effects of Persantine IV (dipyridamole) include:

The dose of intravenous Persantine as an adjunct to thallium myocardial perfusion imaging should be adjusted according to the weight of the patient. The recommended dose is 0.142 mg/kg/minute (0.57 mg/kg total) infused over 4 minutes. Persantine IV may interact with caffeine, adenosine, or cholinesterase inhibitors. Tell your doctor all medications and supplements you use. During pregnancy, Persantine IV should be used only if prescribed. Consult your doctor before breastfeeding.

Our Persantine IV (dipyridamole) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SLIDESHOW

Heart Disease: Symptoms, Signs, and Causes See Slideshow
Persantine IV Consumer Information
SIDE EFFECTS: Consult your pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Read the entire patient information overview for Persantine IV (Persantine)

IMAGES

See Images
Persantine IV Professional Information

SIDE EFFECTS

Adverse reaction information concerning intravenous Persantine® (dipyridamole USP) is derived from a study of 3911 patients in which intravenous Persantine® was used as an adjunct to thallium myocardial perfusion imaging and from spontaneous reports of adverse reactions and the published literature. Serious adverse events (cardiac death, fatal and non-fatal myocardial infarction, ventricular fibrillation, asystole, sinus node arrest, symptomatic ventricular tachycardia, stroke, transient cerebral ischemia, seizures, anaphylactoid reaction, angioedema and bronchospasm) are described above (see WARNINGS). In the study of 3911 patients, the most frequent adverse reactions were: chest pain/angina pectoris (19.7%), electrocardiographic changes (most commonly ST-T changes) (15.9%), headache (12.2%), and dizziness (11.8%).

Adverse reactions occuring in greater than 1% of the patients in the study are shown in Table 1:

Table 1 Drug-Related Adverse Reactions (%) Occurring in Greater than 1% of Patients

 

Incidence (%) of Drug-Related

Adverse Reaction

Adverse Reactions

Chest pain/angina pectoris

19.7

Headache

12.2

Dizziness

11.8

Electrocardiographic Abnormalities/ST-T changes

7.5

Electrocardiographic Abnormalities/Extrasystoles

5.2

Hypotension

4.6

Nausea

4.6

Flushing

3.4

Electrocardiographic Abnormalities/Tachycardia

3.2

Dyspnea

2.6

Pain Unspecified

2.6

Blood Pressure Lability

1.6

Hypertension

1.5

Paresthesia

1.3

Fatigue

1.2

Less common adverse reactions occurring in 1% or less of the patients within the study included:

Cardiovascular System: Electrocardiographic abnormalities (0.8%), arrhythmia (0.6%), palpitation (0.3%), ventricular tachycardia (0.2% see WARNINGS), bradycardia (0.2%), myocardial infarction (0.1% see WARNINGS), AV block (0.1%), syncope (0.1%), orthostatic hypotension (0.1%), atrial fibrillation (0.1%), supraventricular tachycardia (0.1%), ventricular arrhythmia (0.03% see WARNINGS), heart block (0.03%), cardiomyopathy (0.03%), edema (0.03%). Central and Peripheral Nervous System: Hypothesia (0.5%), hypertonia (0.3%), nervousness/anxiety (0.2%), tremor (0.1%), abnormal coordination (0.03%), somnolence (0.03%), dysphonia (0.03%), migraine (0.03%), vertigo (0.03%).

Gastrointestinal System: Dyspepsia (1.0%), dry mouth (0.8%), abdominal pain (0.7%), flatulence (0.6%), vomiting (0.4%), eructation (0.1%), dysphagia (0.03%), tenesmus (0.03%), appetite increased (0.03%).

Respiratory System: Pharyngitis (0.3%), bronchospasm (0.2% see WARNINGS), hyperventilation (0.1%), rhinitis (0.1%), coughing (0.03%), pleural pain (0.03%).

Other: Myalgia (0.9%), back pain (0.6%), injection site reaction unspecified (0.4%), diaphoresis (0.4%), asthenia (0.3%), malaise (0.3%), arthralgia (0.3%), injection site pain (0.1%), rigor (0.1%), earache (0.1%), tinnitus (0.1%), vision abnormalities unspecified (0.1%), dysgeusia (0.1%), thirst (0.03%), depersonalization (0.03%), eye pain (0.03%), renal pain (0.03%), perineal pain (0.03%), breast pain (0.03%), intermittent claudication (0.03%), leg cramping (0.03%). In additional postmarketing experience, there have been rare reports of diarrhea, allergic reaction including urticaria, pruritus, dermatitis and rash. Mesenteric ischemia and mesenteric infarction have also been observed in association with intravenous Persantine® (dipyridamole USP) administration.

Read the entire FDA prescribing information for Persantine IV (Persantine)

QUESTION

In the U.S., 1 in every 4 deaths is caused by heart disease. See Answer
Related Resources for Persantine IV

Read the Persantine IV User Reviews »

© Persantine IV Patient Information is supplied by Cerner Multum, Inc. and Persantine IV Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

SLIDESHOW

Heart Disease: Symptoms, Signs, and Causes See Slideshow

Health Solutions From Our Sponsors

CONTINUE SCROLLING FOR RELATED SLIDESHOW